Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D'Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, Jordan CT. Stevens BM, et al. Among authors: becker mw. Nat Cancer. 2020 Dec;1(12):1176-1187. doi: 10.1038/s43018-020-00126-z. Epub 2020 Oct 26. Nat Cancer. 2020. PMID: 33884374 Free PMC article.
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.
Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. Guzman ML, et al. Among authors: becker mw. Blood. 2007 Dec 15;110(13):4427-35. doi: 10.1182/blood-2007-05-090621. Epub 2007 Sep 5. Blood. 2007. PMID: 17804695 Free PMC article.
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.
Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT. Lagadinou ED, et al. Among authors: becker mw. Cell Stem Cell. 2013 Mar 7;12(3):329-41. doi: 10.1016/j.stem.2012.12.013. Epub 2013 Jan 17. Cell Stem Cell. 2013. PMID: 23333149 Free PMC article.
Defining patient-specific risk in acute myeloid leukemia.
Ho TC, Becker MW. Ho TC, et al. Among authors: becker mw. J Clin Oncol. 2013 Nov 1;31(31):3857-9. doi: 10.1200/JCO.2013.51.4307. Epub 2013 Sep 23. J Clin Oncol. 2013. PMID: 24062389 No abstract available.
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.
Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen FK, Munger J, Crooks PA, Becker MW, Jordan CT. Pei S, et al. Among authors: becker mw. J Biol Chem. 2013 Nov 22;288(47):33542-33558. doi: 10.1074/jbc.M113.511170. Epub 2013 Oct 2. J Biol Chem. 2013. PMID: 24089526 Free PMC article. Clinical Trial.
A phase I study of decitabine and rapamycin in relapsed/refractory AML.
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL 2nd. Liesveld JL, et al. Among authors: becker mw. Leuk Res. 2013 Dec;37(12):1622-7. doi: 10.1016/j.leukres.2013.09.002. Epub 2013 Sep 8. Leuk Res. 2013. PMID: 24138944 Clinical Trial.
150 results